European journal of cancer (Oxford, England : 1990)HumansProto-Oncogene ProteinsProtein-Tyrosine KinasesMaleFemale
Molecular and Clinical characteristics of ROS1 Fusion Variants in ROS1-rearranged Cancers: A Defined Role of Fusion Partners and Breakpoints of ROS1.
Ji-Seon Jeong, Yeokyeong Shin, Shinkyo Yoon, Deokhoon Kim, Josephina Sampson, Richard Bayliss, Jene Choi
Published: 202510.1016/j.ejca.2025.116091
Abstract
INTRODUCTION: ROS1-targeted tyrosine kinase inhibitors (TKIs) are the standard treatment for ROS1-rearranged cancers. We here investigated the therapeutic significance of multiple fusion partners and variable ROS1 genomic breakpoints. METHODS: We ret…
Preview only. Read the full abstract at the source